The capital is pricing GLP-1 receptor agonists as a pharmacological class with a demonstrated aging-rate mechanism. The SELECT trial is a cardiovascular secondary prevention study, not an aging-rate study: NCT03574597 enrolled 17,604 adults with established cardiovascular disease and no prior type 2 diabetes, primary endpoint composite MACE (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke), hazard ratio 0.80 at median follow-up of 39.8 months. Mean age at enrollment was 61.6 years. The cohort was already sick. The 20 percent relative risk reduction in MACE is real. Treating it as a biological aging-rate signal is the extrapolation.

The APAC capital position runs ahead of any registered indication. NMPA's Center for Drug Evaluation approved semaglutide under type 2 diabetes and cardiovascular risk reduction frameworks; HSA Singapore's product registration for semaglutide 2.4mg specifies chronic weight management in adults with BMI above 30, or 27 with weight-related comorbidity. No indication for an aging-rate endpoint exists in either registration. The bet requires a Phase 3 trial. That trial, with a healthy-population cohort, a validated biological-age primary endpoint, and sufficient power to detect a mortality signal, does not appear in the ClinicalTrials.gov registry as of June 2026 under any GLP-1 agonist sponsor.